ABVC BioPharma, Inc. (ABVC)
Company Description
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.
ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Uttam Yashwant Patil Ph.D. |
Contact Details
Address: 44370 Old Warm Springs Blvd. Fremont, California 94538 United States | |
| Phone | 510-668-0881 |
| Website | abvcpharma.com |
Stock Details
| Ticker Symbol | ABVC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001173313 |
| CUSIP Number | 00091F106 |
| ISIN Number | US00091F3047 |
| Employer ID | 26-0014658 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eugene Jiang | Chairman and Chief Business Officer |
| Dr. Howard Doong M.D., Ph.D. | President and Chief Executive Officer |
| Dr. Chi-Hsin King Ph.D. | Chief Scientific Officer |
| Dr. Tsung-Shann Jiang Ph.D. | Chief Strategy Officer, Member of Scientific Advisory Board and Director |
| Leeds Chow | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 29, 2023 | DEF 14A | Other definitive proxy statements |
| Dec 15, 2023 | PRE 14A | Other preliminary proxy statements |
| Nov 20, 2023 | 8-K | Current Report |
| Nov 17, 2023 | 424B4 | Prospectus |
| Nov 17, 2023 | 424B4 | Prospectus |
| Nov 17, 2023 | 424B3 | Prospectus |
| Nov 16, 2023 | 8-K | Current Report |
| Nov 15, 2023 | 8-K | Current Report |
| Nov 15, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |